ABSTRACT Introduction Tecovirimat (TPOXX®; ST-246) was approved for the treatment of
symptomatic smallpox by the USFDA in July of 2018 and has been stockpiled by the US …

Applications of viral vectors have found an encouraging new beginning in gene therapy in
recent years. Significant improvements in vector engineering, delivery, and safety have …

Glioblastoma is the most aggressive form of malignant brain tumor. Standard treatment
protocols and traditional immunotherapy are poorly effective as they do not significantly …

Immuno-oncology (IO) has been an active area of oncology research. Following US FDA
approval of the first immune checkpoint inhibitor (ICI), ipilimumab (human IgG1 k anti-CTLA …

Oncolytic viruses (OVs) are an emerging treatment option for many cancer types and have
recently been the focus of extensive research aiming to develop their therapeutic potential …

Advances in the understanding of cancer immunotherapy and the development of multiple
checkpoint inhibitors have dramatically changed the current landscape of cancer treatment …

Head and neck cancer (HNC), which includes lip and oral cavity, larynx, nasopharynx,
oropharynx, and hypopharynx malignancies, is one of the most common cancers worldwide …

Recent cancer immunotherapy breakthroughs have fundamentally changed oncology and
revived the fading hope for a cancer cure. The immune checkpoint inhibitors (ICI) became …

Glioma tumors are one of the most devastating cancer types. Glioblastoma is the most
advanced stage with the worst prognosis. Current therapies are still unable to provide an …

One of the most prevalent primary malignant brain tumors is glioblastoma (GB). About 6
incidents per 100,000 people are reported annually. Most frequently, these tumors are …